Finance

Lists
Why is 600812 down 4,72%?
Dive Deeper
600812:SHA
North China Pharmaceutical Co Ltd
6,26 CNY
-4,72%
(-0,31) 1D
16 ოქტ, 15:00:00 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600812...
Open
6,33 CNY
High
6,90 CNY
Low
6,10 CNY
Avg. vol.
61,12 მლნ.
Volume
307,76 მლნ.
Dividend
0,56%
Quarterly dividend
0,01 CNY
Ex-dividend date
11 ივნ. 2026
P/E ratio
87,26
52-wk high
6,90 CNY
52-wk low
4,11 CNY
EPS
0,07 CNY
Shares outstanding
1,63 მლრდ.
No. of employees
10 ათ.
Open
6,33 CNY
High
6,90 CNY
Low
6,10 CNY
Avg. vol.
61,12 მლნ.
Volume
307,76 მლნ.
Dividend
0,56%
Quarterly dividend
0,01 CNY
Ex-dividend date
11 ივნ. 2026
P/E ratio
87,26
52-wk high
6,90 CNY
52-wk low
4,11 CNY
EPS
0,07 CNY
Shares outstanding
1,63 მლრდ.
No. of employees
10 ათ.
News stories
From web sources and news partners
Profile
North China Pharmaceutical Group Corp., is a pharmaceutical manufacturer in China. NCPC was one of the key construction projects during China's First Five-Year Plan. After five years of construction since the foundation date in June 1953, the first successful pharmaceutical production, started in June 1958. Being one of the antibiotic producers both in technology and production scale at that time, NCPC created a history of commercial production of antibiotics in China. It has 45 years of development experience. NCPC has been taking the lead in the Chinese pharmaceutical industry in key economic indexes, ranked as one of the Top500 Enterprises and the best profit-makers in China. By the end of 2002, the total assets of the company were valued at US$2 billion, with 18,500 employees. In 2002, NCPC claimed a domestic sales revenue of US$700 million and export sales of US$100 million. Wikipedia
About North China Pharmaceutical Co Ltd
CEO-
Employees9,97 ათ.
Founded20 დეკ. 1992
Headquarters-
SectorPharmaceutical industry
Website-
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
2,21 მლრდ.
1,76 მლრდ.
2,15 მლრდ.
2,07 მლრდ.
Cost of goods sold
1,59 მლრდ.
1,07 მლრდ.
1,53 მლრდ.
1,54 მლრდ.
Cost of revenue
1,59 მლრდ.
1,07 მლრდ.
1,53 მლრდ.
1,54 მლრდ.
Research and development expenses
85,19 მლნ.
85,95 მლნ.
95,62 მლნ.
84,71 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
419,54 მლნ.
414,91 მლნ.
354,22 მლნ.
304,68 მლნ.
Operating expense
504,74 მლნ.
539,54 მლნ.
495,25 მლნ.
396,76 მლნ.
Total operating expenses
2,09 მლრდ.
1,61 მლრდ.
2,03 მლრდ.
1,94 მლრდ.
Operating income
116,01 მლნ.
149,57 მლნ.
128,11 მლნ.
125,58 მლნ.
Other non operating income
-299,86 ათ.
-2,96 მლნ.
-10,58 მლნ.
6,02 მლნ.
EBT including unusual items
73,18 მლნ.
70,19 მლნ.
66,28 მლნ.
57,65 მლნ.
EBT excluding unusual items
45,54 მლნ.
84,31 მლნ.
61,80 მლნ.
58,08 მლნ.
Income tax expense
23,93 მლნ.
24,28 მლნ.
16,90 მლნ.
16,15 მლნ.
Effective tax rate
32,70%
34,59%
25,50%
28,02%
Other operating expenses
4,82 მლნ.
29,30 მლნ.
27,82 მლნ.
15,57 მლნ.
Net income
35,01 მლნ.
24,55 მლნ.
35,47 მლნ.
28,37 მლნ.
Net profit margin
1,58%
1,40%
1,65%
1,37%
Earnings per share
-
-
-
-
Interest and investment income
19,41 მლნ.
27,71 მლნ.
19,26 მლნ.
22,40 მლნ.
Interest expense
-85,85 მლნ.
-85,06 მლნ.
-74,99 მლნ.
-76,52 მლნ.
Net interest expenses
-66,43 მლნ.
-57,35 მლნ.
-55,73 მლნ.
-54,13 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
313,14 მლნ.
371,92 მლნ.
350,45 მლნ.
367,38 მლნ.
Gain or loss from assets sale
-9,85 ათ.
-827,34 ათ.
-
-217,80 ათ.
AI content may include mistakes. Learn more
Google აპები